Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma completed recruitment for its phase 2b study. 11 of the 20 listed, Danish biotech companies have published news the past week. 7 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide tops chart of best performing stick this year.
Company news the past week
Ascendis Pharma
Ascendis Pharma Reports First Quarter 2023 Financial Results (LINK)
No news the past week
Cessatech
No news the past week
CS MEDICA Joint Venture, RongShi MEDICA (Ordos) Co. Ltd., update (LINK)
No news the past week
Evaxion Biotech
Fourth quarter and full year 2022 financial results and business update (LINK)
Expres2ion
No news the past week
Fluoguide
No news the past week
Genmab
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen (LINK)
Gubra
Gubra announces the end of the stabilisation period (LINK)
Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares (LINK)
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
Pila Pharma AB publishes annual report for 2022 (LINK)
Pila Pharma AB publishes interim report (1 January – 31 March 2023) (LINK)
Saniona
Saniona publishes its Annual Report for 2022 (LINK)
Scandion Oncology
No news past week
SynAct Pharma
SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis (LINK)
ViroGates
No news past week
Zealand Pharma
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (LINK)
Y-mAbs Therapeutics
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 (LINK)
2cureX
2cureX’s CEO Fernando Andreu purchases shares in the company (LINK)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
There were mixed developments among the Danish Biotech stocks last week. The average return was -1,4%. 2CureX AB rose the most with 11% after their CEO bought shares. SynAct Pharma AB also performed nicely after they completed the recruitment for their Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis. On the other hand, Biosergen AB and Evaxion Biotech A/S became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have delivered a negative return. However, the average return year-to-date is positive at 2,1% because a few companies as especially Fluoguide AB and Saniona AB have done really well.
Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment
